Gilead : Phase 3 Study Of Trodelvy In Metastatic Urothelial Cancer Fails To Meet Primary Endpoint
31/5 03:14
(RTTNews) - Gilead Sciences Inc. (GILD) said that the confirmatory Phase 3 TROPiCS-04 study of Trodelvy in locally advanced or metastatic urothelial cancer did not meet the primary endpoint of overall survival....